Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc. is a NASDAQ-listed common stock of a biopharmaceutical company focused on therapies for people living with autoimmune diseases that have high unmet medical needs in the United States and Japan. The company markets LUPKYNIS (voclosporin), an oral treatment for adults with active lupus nephritis, and is developing aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand, for potential use in autoimmune diseases. Founded in 1993, Aurinia is headquartered in Edmonton, Canada.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AUPH
|
$8.44
|
-45.3% Downside
|
Overvalued
|
$17
|
10.1% Upside
|
Fair
|
Excellent
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
6.6x
|
3.5x
|
6.6x
|
1.961 B
|
1.671 B
|
3.4%
|
98.2%
|
9.1
|
—
|
55.9%
|
